Animal Model Development for Chronic Inflammation

Chronic inflammation (CI), characterized by unresolved inflammation persisting for prolonged periods, can exacerbate tissue damage in various organs. Understanding the cellular and intracellular pathways involved in CI is crucial for developing effective treatments. Animal models play a significant role in studying CI mechanisms and in developing new therapies for various chronic conditions, such as cardiovascular diseases, high blood pressure, obesity, Alzheimer’s, rheumatoid arthritis, asthma, and multiple sclerosis.

Among the commonly used animals for CI studies, mice stand out due to their high genomic similarity to humans (approximately 97.5%). Specifically, C57BL/6 and Balb/c mice are popular strains in experimental research. These mice possess distinct immune response characteristics that make them suitable for modeling different aspects of chronic inflammation.

C57BL/6 mice exhibit a robust Th1 immune response and produce high levels of Interferon-gamma (IFN-Ρƒ), making them suitable for modeling conditions characterized by Th1-driven inflammation. They also have a highly active complement system and demonstrate ease in inducing immune tolerance.

On the other hand, Balb/c mice display a strong Th2 immune response, making them ideal for modeling allergic reactions and certain infectious diseases. They exhibit high production of IgG1 and IgA antibodies, along with elevated complement activity but lower interferon production compared to C57BL/6 mice. Additionally, Balb/c mice generate a more potent humoral response against antigens compared to the C57BL/6 strain.

The utilization of these mouse strains in experimental studies allows researchers to mimic specific aspects of chronic inflammation observed in humans, facilitating a deeper understanding of CI mechanisms and the development of targeted therapeutic interventions.

1 thought on “Animal Model Development for Chronic Inflammation”

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top

Dr. Fatima Tariq,

Business Development Officer

Dr. Fatima Tariq, Pharm.D is a pharmacy professional with experience across the retail, hospital, and pharmaceutical sectors. She earned her Doctor of Pharmacy degree from Akhtar Saeed College of Pharmaceutical Sciences, affiliated with the University of the Punjab.

She began her career as an IPD Pharmacist at Hameed Latif Hospital and later transitioned into business development within the pharmaceutical industry. Currently, she serves as a Business Development Officer at Trial 360.

Her expertise includes business development strategies, client relationship management, market research, competitive analysis, stakeholder engagement, and identifying growth opportunities. Combining pharmaceutical knowledge with commercial insight, she is committed to fostering strategic partnerships and driving sustainable business growth within the healthcare and clinical research landscape.